• ABOUT US
  • OUR TEAM
    • BOARD
    • MANAGEMENT TEAM
    • PORTFOLIO COMPANY CEO’S
    • FINANCE
    • SCIENTIFIC ADVISERS
  • PORTFOLIO
    • CORE PORTFOLIO
    • SEED PORTFOLIO
  • INVESTORS
    • RNS ANNOUNCEMENTS
    • REPORTS AND PRESENTATIONS
    • FINANCIAL RESULTS
    • ANALYST COVERAGE
    • CORPORATE GOVERNANCE
    • FUNDRAISING
    • STRATEGIC REVIEW
  • NEWS
  • CONTACT US
No announcement available or all announcement expired.
NSCI (LON) 5,50 GBX
  • ABOUT US
  • OUR TEAM
    • BOARD
    • MANAGEMENT TEAM
    • PORTFOLIO COMPANY CEO’S
    • FINANCE
    • SCIENTIFIC ADVISERS
  • PORTFOLIO
    • CORE PORTFOLIO
    • SEED PORTFOLIO
  • INVESTORS
    • RNS ANNOUNCEMENTS
    • REPORTS AND PRESENTATIONS
    • FINANCIAL RESULTS
    • ANALYST COVERAGE
    • CORPORATE GOVERNANCE
    • FUNDRAISING
    • STRATEGIC REVIEW
  • NEWS
  • CONTACT US

Dr. Bedu-Addo to Chair the Therapeutics/Cancer Immunotherapies Session and Present Phase I/IIA Results

Sep 19, 2016
-
PDS Biotechnology
FacebookTweetLinkedin
← PREVIOUS POST
Wanda Technology Selected by 24Hr HomeCare
NEXT POST →
Glycotest strengthens IP portfolio
News
  • Appointment to the Board
  • PDS collaborates with Merck in Phase 2 studies
  • PDS prioritise PDS0101 in High risk HPV to Phase 2
  • PDS – positive data for immunotherapy treatment
  • Interim Results for six months ended 30 June 2019
INVESTORS
  • RNS Announcements
  • Presentations
  • Financial Results
  • Financial Calendar
  • Analyst Coverage
  • Investment Strategy
  • Corporate Governance
  • News
Categories
  • Glycotest
  • Media
  • News
  • PDS Biotechnology
  • ProAxsis
  • RNS Announcements
Archives
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • July 2014
  • June 2014
  • May 2014
  • March 2014
  • February 2014
  • September 2013

NetScientific plc

PO Box 76075
London
EC3P 3DX

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

  • RNS Announcements
  • Presentations
  • Financial Results
  • Financial Calendar
  • Analyst Coverage
  • Investment Strategy
  • Corporate Governance
  • News
copyright
Terms of Use
Dr. Bedu-Addo to Chair the Therapeutics/Cancer Immunotherapies Session and Present Phase I/IIA Results - NetScientific